In the mid-1980s, a new approach to the treatment of migraine was researched, in the form of the first relatively selective 5-HT 1B/1D receptor agonist, sumatriptan. Sumatriptan was designed as an analogue of the serotonin molecule. The first formulation of sumatriptan, introduced in 1991, was a subcutaneous injection; this was followed by the oral and finally, the intranasal preparations. It became evident that sumatriptan was an effective treatment of acute migraine, both with and without aura.
currently available. Eletriptan, frovatriptan and almotriptan are not currently marketed in Canada.
Since sumatriptan was the first available triptan, it has the most extensive data supporting its eff i c a c y, safety and tolerability. A systematic review of the efficacy and adverse effects of subcutaneous, oral and intranasal sumatriptan has been recently published. 3 Although the newer triptans have less extensive data, they possess features such as improved b i o a v a i l a b i l i t y, increased lipophilicity and central nervous system penetration and, in the case of naratriptan, a longer halflife.
In 1997 and 1998, the Canadian Headache Society published guidelines for the diagnosis and management of migraine (pharmacologic) and for the nonpharmacologic management of migraine in adults. 4, 5 At the time of publication of the guidelines, sumatriptan was the only available triptan. This review will give information on triptans currently available in Canada.
PURPOSE OF THE REVIEW
This review is an attempt to consolidate evidence concerning the efficacy and tolerability of triptans currently available in Canada (i.e., sumatriptan, naratriptan, zolmitriptan, rizatriptan) for the acute or symptomatic treatment of migraine and to provide some guidelines for the selection of a triptan. Randomized, placebo-controlled studies and direct comparative studies (published in full) were primarily selected for review (see Methodology). These studies are available in the public domain. Data are often presented in the form of abstracts or posters at medical meetings; review of such data has not been included, since it is difficult to evaluate.
METHODOLOGY
A search of the MEDLINE database from 1980 -March 2000 was conducted. Randomized, placebo-or comparator-controlled trials, published in full, were primarily selected for the review. Other references quoted include: guidelines, systematic reviews, open label studies, retrospective studies, population-based studies, pharmacokinetic/drug interaction studies, manufacturers product monographs and letters to the editor. MeSH headings/textwords used included: migraine, sumatriptan, naratriptan, zolmitriptan, rizatriptan. Data from randomized, placebo-controlled trials were pooled for each individual triptan (separately for each strength and dosage form, excluding naratriptan 1 mg oral and rizatriptan 5 mg oral). Statistical assessment of homogeneity of trials was not performed. Statistical variables were calculated using EXCEL version 5.0: 1. Therapeutic gain: the percentage response to the active drug minus the percentage response to placebo at the same time point in the study. 2. N u m b e r needed to treat (NNT): the reciprocal of therapeutic gain. The number of people needed to treat with active drug before a positive response is observed (over and above the response provided by placebo). 3. Therapeutic penalty: the percentage of subjects experiencing an adverse event with the drug minus the percentage experiencing an adverse event with placebo (all recorded adverse events). 4. N u m b e r needed to harm (NNH): the reciprocal of therapeutic penalty. The number of subjects needed to treat with active drug before a negative event is observed. 5. 95% confidence intervals (CI): calculated using the following formulae: Confidence interval of the proportion (p) of responders: _______ 95% CI (p) = p ± 1.96 √p(1-p)/n Confidence interval of the therapeutic gain or therapeutic penalty: placebo response (p) minus active response (a) ________________ 95% CI (p-a) = (p-a) ± 1.96 √p(1-p)/n + a(1-a)/m Confidence interval of the NNT (or NNH) : the reciprocal of the CI for the therapeutic gain (or penalty). Randomized controlled trials excluded from the analysis included those utilizing doses not currently available or recommended, nonstandard endpoint measurements (e.g., headache relief at four hours), special populations (e.g., menstrual migraine) and those that were not placebo-controlled.
Efficacy
Problems in the assessment of efficacy arose during the development of the triptans. A simplistic verbal response scale, with patients reporting severe, moderate, mild or no pain, superceded traditional methods of assessing pain relief based on visual analog scales. A 'headache response' is classified as a reduction in headache pain from severe or moderate to mild or none; therefore, patients who have a reduction of pain from moderate to mild are classified as 'responders'. A much more robust method of assessing efficacy is based on the concept of 'pain-free'. Studies also vary in the predetermined time point for assessing efficacy; two hours is the usual endpoint. Efficacy at one hour can now be assessed with the introduction of drugs that are more rapidly absorbed. However, for naratriptan, which is slowly absorbed, four-hour data has been primarily reported in clinical trials.
The endpoints for efficacy include: 1. Headache response at one or two hours: the percentage of patients whose headache severity is reduced from 'severe or moderate'at baseline to 'mild or none', one or two hours after taking a dose. 2. Pain-free at one or two hours: the percentage of patients whose headache severity is reduced from 'severe or moderate'at baseline to 'none', one or two hours after taking a dose. 3. Clinical disability score of 0/1 at two hours: the percentage of patients who rate their daily activities as 'mildly impaired'or 'normal', two hours after taking a dose. 4. Recurrence: the percentage of patients who, having obtained a response or freedom from headache pain within two hours of taking a dose, develop a worsening (moderate/severe headache pain) within 24 hours of the initial dose.
Adverse events
Reporting of adverse events has also been a problem. Most studies quote the incidence of adverse events occurring above a certain predetermined percentage, which varies from study to study (e.g., greater than 3%, 5%, etc.). The categorization of adverse events has also been difficult to unify. Different studies have quoted different types of adverse events. In some studies, adverse events have been captured from patient diaries, while others have been collected retrospectively.
The endpoints for safety/tolerability include: Overall incidence of adverse events: the percentage of patients who, having taken the drug, experience an unexpected or undesired event (includes all adverse events, not just drug-related).
PHARMACOLOGY OF THE TRIPTANS
The triptans are serotonin derivatives displaying highly selective and potent agonist activity at the vascular 5-HT 1B receptor and the neuronal 5-HT 1D receptor. The mode of action of the triptans is hypothesized to be three-fold 6 (Table 1) Subcutaneous sumatriptan has the best bioavailability and most rapid absorption of all the triptans. However, the bioavailability of oral and intranasal sumatriptan is low, primarily due to first pass metabolism and partly due to incomplete absorption. 7 The newer triptans all have better oral bioavailability than sumatriptan, with naratriptan having the greatest bioavailability. [8] [9] [10] Whether better oral bioavailability translates into a more consistent clinical response has not been determined. The presence of gastric stasis, which frequently accompanies a migraine attack, may delay the absorption of oral medications. 11 The time to reach peak concentration (T max ) is significantly increased during an attack with oral zolmitriptan, 12 but not with oral sumatriptan 7 or rizatriptan. 10 Rizatriptan (oral tablet) reaches maximum serum levels within 1-1.5 hours during an attack. Food delays absorption of the oral tablet by about one hour. Rizatriptan wafer is a freeze-dried formulation, which rapidly disintegrates on the tongue (within seconds), is swallowed with saliva and absorbed from the gastrointestinal tract (i.e., not sublingual); absorption is somewhat slower compared to the oral tablet.
PHARMACOKINETICS
1 0 Naratriptan has the longest elimination half-life and hence, the longest duration of action of the triptans. 8 Naratriptan, rizatriptan and zolmitriptan are all more lipophilic (i.e., more likely to cross the blood-brain barrier) than sumatriptan; however, the clinical significance of differences in lipophilicity is not yet clear.
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All triptans are metabolized in the liver. [7] [8] [9] [10] Sumatriptan is metabolized by monoamine oxidase A (MAO-A), which is found in the liver and gastrointestinal tract. 7 Naratriptan is metabolized by cytochrome P-450 CYP-450) enzymes (exact isoenzymes are not known). 8 The metabolism of zolmitriptan involves both cytochrome P-450 (1A2 isoenzyme (CYP1A2)) and MAO-A. Zolmitriptan is metabolized to an active N-desmethyl metabolite, which is two to six times more potent than the parent compound and may contribute to the overall efficacy. 9, 12 Rizatriptan is primarily metabolized by MAO-Ato inactive metabolites and an active N-monodesmethyl metabolite (with activity similar to that of the parent compound).
10,13
DRUG INTERACTIONS (Table 2) Monoamine oxidase inhibitors (MAOIs) Since sumatriptan, rizatriptan and zolmitriptan are metabolized by MAO-A, drugs that inhibit MAO-Aare likely to interact with these triptans. Selective MAO-A inhibitors (e.g., moclobemide) or nonselective MAOIs (e.g., phenelzine, tranylcypromine) may inhibit the metabolism of these triptans, resulting in increased plasma concentrations. MAOIs also inhibit the degredation of serotonin, thereby increasing the concentration of serotonin in the synapse. As a result, serotonin syndrome may potentially occur with concomitant use of MAOIs and triptans (see discussion below on serotonin syndrome). The concurrent administration, or use of sumatriptan, rizatriptan or zolmitriptan within two weeks of discontinuation of MAOI therapy is contraindicated.
7 , 9 , 1 0 , 1 4 Since naratriptan is not metabolized by MAO-A, its use is not contraindicated with MAOIs (but there is a theoretical possibility of serotonin syndrome -see below).
Ergot-containing drugs and other 5-HT 1 agonists
Due to the theoretical possibility of additive vasospastic reactions (including coronary vasospasm), manufacturers of triptans contraindicate their use within 24 hours before, or after, treatment with ergot-containing drugs or their derivatives (e.g., ergotamine, dihydroergotamine, methysergide) or other 5-HT 1 agonists (i.e., other triptans). [7] [8] [9] [10] However, in clinical practice, neurologists sometimes prescribe triptans for patients who are receiving methysergide as prophylactic therapy; careful monitoring for adverse effects is advised in this situation. Different dosage forms of the same triptan can be taken within a 24-hour period, after an appropriate interval (generally two hours).
Serotonergic drugs
Since the triptans are serotonin receptor agonists, concurrent use with other serotonergic drugs [e.g., MAOIs, selective serotonin reuptake inhibitors (SSRIs), lithium] may result in serotonin syndrome. Features of the serotonin syndrome include: mental status and behavioural change (e.g., agitation, excitement, hypomania, obtundation), motor system involvement (e.g., myoclonus, hemiballismus, tremor, hyperreflexia, motor weakness, dysarthria, ataxia) and autonomic symptoms (e.g., fever, chills, diarrhea). Not all of these symptoms are necessarily present in each case. Serotonin syndrome can be relatively mild or, in rare cases, may be life-threatening. There have been some case reports of 'suspected'serotonin syndrome with sumatriptan used in combination with SSRIs or lithium; however, other reports have not noted adverse effects with these combinations. Since serotonin syndrome is, theoretically, possible with concurrent use of any of the triptans and other serotonergic drugs, such as SSRIs (e.g., fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram) or lithium, caution is advised. 15, 16 In clinical practice, triptans are usually well-tolerated in patients on SSRI therapy. 1 3 , 1 7 Tricyclic antidepressants, venlafaxine, 
Naratriptan
Rizatriptan Sumatriptan Zolmitriptan *MAOIs include selective MAO-Ainhibitors (i.e., moclobemide) and non-selective MAOIs (e.g., phenelzine, tranylcypromine) † Ergot derivatives include ergotamine, dihydroergotamine (DHE), methysergide ‡SSRIs include fluoxetine, fluvoxamine, paroxetine, sertraline, citalopram; interaction is unlikely with tricyclic antidepressants, venlafaxine, nefazodone or bupropion SS = serotonin syndrome; AUC = area under the plasma-concentration-time curve; C max = maximum plasma concentration; BP= blood pressure nefazodone or bupropion are unlikely to result in serotonin syndrome when used in combination with triptans.
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Beta-blockers Concomitant use of propranolol has resulted in increased bioavailability and serum concentrations of rizatriptan 10 and z o l m i t r i p t a n . 1 4 , 1 8 The interaction with zolmitriptan is not considered to be clinically significant and no dosage adjustments are necessary. 9 For rizatriptan, use of 5 mg as a single dose (maximum 10 mg/d) is recommended with concomitant propranolol therapy; however, no interactions have been noted with concomitant use of nadolol or metoprolol. 10 Sumatriptan and naratriptan have not been reported to interact with propranolol. 8, 19 Cimetidine Concomitant use of cimetidine has been found to increase the half-life and bioavailability of zolmitriptan and its active metabolite. Therefore, a total dose of 5 mg in a 24-hour period should not be exceeded. This recommendation also applies to concomitant use of zolmitriptan with other CYP1A2 inhibitors (e.g., fluvoxamine, ciprofloxacin), since a similar interaction may occur, theoretically. 9 Cimetidine has not been reported to interact with the other triptans. (Tables 3-5) Headache response rates at one and two hours are presented in Table 3 . The lowest NNT for headache response at one and two hours is observed with subcutaneous sumatriptan (1.96 and 2.01, respectively). Among the oral formulations, the lowest NNT for headache response at two hours is observed with rizatriptan wafer (2.15, based on one trial). Naratriptan has the highest NNT (5.06) at two hours. However, differences among most of the oral/intranasal triptans are relatively small at two hours.
EFFICACY RESULTS a) Randomized placebo-controlled trials
Pain-free rates at one and two hours are presented in Table 4 . The lowest NNT for pain-free at one and two hours is observed with subcutaneous sumatriptan (2.69 and 2.64, respectively). Among the oral triptans, the lowest NNT for pain-free at two hours is observed with rizatriptan wafer (3.08, based on one trial) and rizatriptan oral tablet (3.15). Naratriptan has the highest NNT (6.49) at two hours. As for response rates, differences among most of the oral/intranasal triptans are relatively small at two hours. For a clinical disability score 0/1 at two hours (Table 5) , the lowest combined NNT is observed with subcutaneous sumatriptan (2.34). Among the oral formulations, the lowest combined NNT is observed with rizatriptan wafer (3.15, based on one trial) and rizatriptan oral tablet (3.72).
b) Direct comparative trials

Zolmitriptan vs Sumatriptan
Zolmitriptan (2.5 mg and 5 mg) has been compared to sumatriptan (25 mg and 50 mg) oral tablets in a randomized, double-blind, parallel-group study (N=1212). In this comparison, zolmitriptan 2.5 mg was significantly more effective than the sumatriptan 25 and 50 mg at two and four hours, in terms of headache response. Zolmitriptan 5 mg was better than sumatriptan 25 mg at all time points, and against sumatriptan 50 mg at one hour and four hours. Pain relief over 24 hours was also assessed; both doses of zolmitriptan showed significantly better pain relief for up to six attacks treated, than either dose of sumatriptan. 20 
Rizatriptan vs Naratriptan
Rizatriptan (10mg) has been compared to naratriptan (2.5mg) mg in a randomized, double-blind, double-dummy, placebocontrolled study (N=522). Rizatriptan was more effective than naratriptan and provided earlier headache relief (as early as 30 minutes). Significantly more patients were pain-free at two hours with rizatriptan than with naratriptan. Rizatriptan also provided earlier relief of associated migraine symptoms (i.e., nausea, photophobia, phonophobia) within two hours and more patients had normal functioning at two hours, compared to those on naratriptan. Patients on rizatriptan were more satisfied with their medication at two hours. However, there was no significant difference at 24 hours, in terms of overall treatment effect. 21 
Rizatriptan vs Sumatriptan
An early, randomized, double-blind, parallel-group, doseranging study (N=449) compared rizatriptan 10 mg, 20 mg and 40 mg to placebo and to sumatriptan 100 mg (rizatriptan 20 mg and 40 mg are not currently available in Canada). In terms of pain relief, rizatriptan 10 mg was not significantly different from sumatriptan 100 mg at one and two hours. 22 Rizatriptan (5 mg and 10 mg) has been compared to sumatriptan (25 mg and 50 mg) and placebo in a randomized, double-blind, crossover study (N=1329). Rizatriptan 5 mg was superior to sumatriptan 25 mg for pain relief at one and two hours. Rizatriptan 10 mg was superior to sumatriptan for 'painfree'at one hour and four hours. Sumatriptan 25 mg was superior to rizatriptan 5 mg at 0.5 hours. Rizatriptan (5/10 mg) resulted in a greater reduction in the associated symptom of nausea, compared to sumatriptan (25/50 mg). Functional disability results showed that rizatriptan 5 mg was superior to sumatriptan 25 mg at 0.5 and 1.5 hours, while rizatriptan 10 mg was superior to sumatriptan 50 mg at three hours and four hours. Patients experienced more satisfaction with rizatriptan 10 mg versus sumatriptan 50 mg at two hours and four hours. No difference was detected between rizatriptan 5 mg and sumatriptan 25 mg in terms of patient satisfaction. 23 A randomized, double-blind, triple-dummy, parallel-group trial (N=1091) compared rizatriptan (5 mg and 10 mg) and sumatriptan (100 mg) and placebo. Results were age-adjusted, since the rizatriptan group was younger than the sumatriptan group. Rizatriptan 10 mg had a faster time to pain relief through two hours than sumatriptan 100 mg, demonstrating significantly more effect at one hour. Rizatriptan 10 mg was superior to sumatriptan 100 mg for pain-free at two hours. Compared to the sumatriptan group, significantly more patients in the rizatriptan 10 mg group were without nausea at all time points through two hours. More patients showed improvement in functional disability at one hour and two hours with rizatriptan 10 mg. Adverse events were less frequent with rizatriptan 5 mg (i.e., chest pain, any adverse event and any drug-related adverse event) compared to sumatriptan 100 mg. Rizatriptan 10 mg showed fewer drug-related adverse events compared to sumatriptan 100 mg.
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RELIEF OF ASSOCIATED SYMPTOMS
The associated symptoms of migraine (i.e., nausea, vomiting, photophobia, phonophobia) contribute to migraine-related disability. Therefore, relief of associated symptoms is important in the overall management of migraine. The most distressing symptoms are gastrointestinal disturbances, which can be severe and incapacitating. During migraine attacks, nausea and anorexia occur in a significant proportion of patients; vomiting occurs less frequently. Approximately 30% of patients indicate that nausea interferes with their ability to take oral migraine medications. 25 Based on data from direct comparative trials (see above), rizatriptan appears to provide earlier and better relief of migraine-associated nausea than sumatriptan 23, 24 or naratriptan.
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CONSISTENCY OF RESPONSE
The measurement of consistency of response is sometimes difficult since, in clinical practice, patients treat large numbers of attacks. The reasons for lack of response in some attacks are not known. Consistency can be measured in different ways: by utilizing group data (a number of patients treat a large number of attacks) and determining the percentage of responders at each headache treatment or by determining response rates in individual patients treating a number of attacks. Utilizing group data has a disadvantage, since patients who do not respond will drop out eventually and the process will select consistent responders. Determining consistency of response in individual patients is more clinically meaningful. Consistency studies have been published using group data for all the triptans, [26] [27] [28] [29] [30] [31] [32] [33] and using individual (intra-patient) data for sumatriptan 3 4 a n d rizatriptan. 35 
ADVERSE EVENTS/SAFETY
The combined NNH for overall incidence of adverse events is shown in Table 6 . The lowest combined NNH occurs with subcutaneous sumatriptan (3.25) . Oral rizatriptan and oral sumatriptan (100 mg) have similar combined NNH for overall incidence of adverse events (7.10 and 7.13, respectively). The results for oral zolmitriptan and oral naratriptan are inconsistent, with very large confidence intervals.
Triptan symptoms/chest symptoms
Naratriptan appears to have the best tolerability profile of the triptans, having a low incidence (similar to that of placebo) of triptan-type sensations (e.g., tightness of jaw/neck/chest, chest discomfort, paresthesias, flushing, heat sensations, dizziness, somnolence). 36, 37 It should be emphasized that while all triptans are generally well-tolerated, this must not be confused with safety. Since 5-HT 1B receptors are found on human coronary arteries, triptans have the potential to constrict coronary vessels; this constriction is usually insignificant in patients without underlying coronary heart disease. 'Chest symptoms'associated with the triptans are often described as a tightness, squeezing, heaviness or pain. Sometimes the pain extends to, or is confined to, the throat. These symptoms are not generally due to coronary vasoconstriction, since electrocardiographic abnormalities are rare. However, there have been reported cases of myocardial infarction with sumatriptan (available on market for the longest time) but not with the other three triptans, to date. Nevertheless, considering the large total number of doses taken, the absolute risk of myocardial infarction appears to be very small with sumatriptan or other triptans. 38 All available triptans have a similar potential to cause coronary vasoconstriction 3 9 a n d , therefore, should be avoided in patients with underlying cardiovascular or cerebrovascular diseases or those who have risk factors for such diseases, or in patients with uncontrolled hypertension.
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Sulfonamide allergy
Sumatriptan and naratriptan contain sulfonamide moieties, while zolmitriptan and rizatriptan do not. Sumatriptan and naratriptan should be used with caution in patients who have a history of sulfonamide (sulfa) allergy; risks and benefits should be assessed.
7 -1 0 H o w e v e r, sumatriptan and naratriptan are structurally different from the sulfonamide antimicrobial agents; the actual incidence of cross-reactivity with sulfonamides is not presently known.
Pregnancy/lactation
Interim results from an ongoing sumatriptan/naratriptan pregnancy registry (Glaxo Wellcome) are insufficient for drawing conclusions about the safety of sumatriptan use in pregnancy. The birth defect rate for sumatriptan users does not appear to differ from the expected rate of 3% (2-5%); no pattern has been observed in reported defects, to date. 4 0 A n o t h e r population-based, retrospective study (N=34) found that sumatriptan exposure during pregnancy was associated with an increased risk of preterm delivery and low birth weight. 41 To date, no data are available for naratriptan, zolmitriptan or rizatriptan use during pregnancy. The manufacturers of triptans do not recommend their use during pregnancy. [7] [8] [9] [10] Sumatriptan is excreted in breast milk; the estimated amount is 3.5% of the dose taken by the mother. If breast milk is discarded for eight hours after a dose, a negligible amount would be present in the breast milk. 42 However, the manufacturer recommends avoiding breastfeeding for 24 hours after a dose of sumatriptan. 7 No data are available on breast milk excretion for naratriptan, zolmitriptan or rizatriptan; the manufacturers advise caution.
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HEADACHE RECURRENCE
Recurrence is the return of a headache to moderate or severe intensity within 24 hours, after it has become mild or absent (pain-free) in the first two hours. After a two-hour response, the recurrence rates range from 21-40% for sumatriptan, [22] [23] [24] 34, 54, 72 35-47% for rizatriptan 2 2 -2 4 , 3 5 , 4 3 , 5 8 , 5 9 and 22-37% for zolmitriptan. 30, 44, 45, 60, 61 Recurrence rates for naratriptan appear to be somewhat lower (17-28%, after a four-hour response). 46 The reason for the lower headache recurrence rate with naratriptan is unknown. [7] [8] [9] [10] Recommended doses and availability are shown in Table 7 .
RECOMMENDED DOSES AND AVAILABILITY
DISCUSSION
The introduction of sumatriptan in the early 1990s revolutionized acute migraine therapy and resulted in an increased understanding of migraine pathophysiology. T h i s review has attempted to consolidate evidence concerning efficacy and tolerability of the four available triptans. Data from placebo-controlled and direct comparative trials of triptans, which have been published in full (to date), have been utilized. Data from abstracts or posters presented at meetings has not been included since such data are difficult to evaluate. Direct comparative studies are best for comparing relative efficacy of medications. However, there are few direct comparative trials of triptans published in full. Therefore, data from placebocontrolled trials have been pooled and combined NNTs or NNHs have been calculated for each triptan (according to dosage form and strength).
Interpretation of relative NNT or NNH among the different triptans should be undertaken with caution, since trial designs and patient populations may diff e r. Conclusions regarding relative efficacy, based on pooled data from placebo-controlled trials, are difficult to make. For naratriptan, four-hour efficacy data is usually presented in trials, since it has a slow onset of action; however, four-hour data have not been included in this review.
Patient preference:
What do patients want from their acute migraine medication? This has been reviewed by Silberstein. 25 The top three were:
1. Provides quick headache relief 2. Decreases headache pain 3. Decreases likelihood of headache recurrence
Onset of headache relief: Subcutaneous sumatriptan has the most rapid onset of action. Among the oral triptans, rizatriptan appears to have the fastest onset.
Efficacy (headache pain reduction):
Subcutaneous sumatriptan is more effective than the oral/intranasal triptans; it may be considered for patients who do not respond to oral/intranasal triptans. Among the oral triptans, rizatriptan appears to have the best efficacy; however, differences among the oral triptans (except for naratriptan) are not great. Although naratriptan appears to be less effective than the other triptans, it may be very effective for some patients. Triptans are effective when taken at any stage of a migraine attack; however, they appear to have greater efficacy when taken earlier in an attack.
Relief of associated symptoms of migraine, particularly nausea/vomiting, is also important. Rizatriptan appears to provide earlier and better relief of migraine-associated nausea than the other available triptans.
Does lack of response to one triptan predict lack of response to another? This would not seem to be the case. One open trial Based on an evaluation of clinical parameters that may affect headache recurrence with naratriptan, lower recurrence rates were noted in patients who treated their attacks earlier (i.e., within three hours of onset) and in those obtaining complete relief (pain-free) within four hours postdose. 46 Whether this also applies to other triptans remains to be established.
Consistency:
Consistency in response is becoming more important as an efficacy endpoint. Studies evaluating consistency have been performed for all four drugs; however, care must be employed when interpreting the data. In some studies, patients treated a large number of attacks over many months (group data), which selected consistent responders sequentially. Consistency among the triptans should ideally be compared utilizing intra-patient data obtained from direct comparative clinical trials.
Tolerability/Safety: The matter of tolerability vs. safety is problematic. Safety is always a great concern; for a nonfatal condition such as migraine, a medication that causes serious adverse events is not appropriate. Recent reviews suggest that the triptans are generally safe, considering the large number of attacks treated, to date. The more frightening symptoms are those which involve 'chest sensations'; these sensations are general throughout the class. However, they do not seem to presage the onset of more serious cardiac problems.
Which triptan to start with? This is an extremely difficult question to answer; based on the randomized controlled trials available, there is no clear-cut winner in the group. A small advantage in rapidity of onset within a group may not be apparent in an individual. A small difference in the tolerability may not be apparent either. It is clear from all the studies that the most rapidly-acting and the most effective treatment is sumatriptan subcutaneous injection. It was the first to be licensed in Canada, yet experience has shown that many patients do not accept an injection as well as an oral dosage form (this does not include cluster headache patients, in whom this preparation is the most effective symptomatic treatment available for acute attacks of cluster). The intranasal route would seem intuitively to have a faster onset of action; however, results are inconsistent, possibly due to the fact that patients may not use the device properly or some of the medication may be swallowed. There may be a problem with bitter taste (e.g., sumatriptan nasal). The novel, orally-disintegrating form (wafer) of rizatriptan (RPD) appears to be more popular than the standard tablet form. The characteristics of the headache (e.g., severity, time to peak intensity, degree of disability, time to disability) may be considered in selecting a particular triptan. If the headache has a rapid progression to severe intensity, with a high degree of associated disability, a rapid onset medication (e.g., subcutaneous sumatriptan) may be the best option. Oral rizatriptan also has a fairly rapid onset of action. A slowly developing headache, which has a long time course, may be treated by a triptan with relatively slow onset but longer duration of action (e.g., naratriptan). For patients experiencing nausea and vomiting with their attacks, nonoral routes of administration should be considered (e.g., subcutaneous, intranasal). A l t e r n a t i v e l y, an orally-disintegrating tablet/wafer may be considered for patients experiencing nausea without vomiting (rizatriptan wafer is absorbed in gastrointestinal tract). Patients who experience many triptan adverse events may be tried on naratriptan, which tends to have a milder adverse effect profile than the other triptans. Patient preference may also be considered. An orally-disintegrating tablet formulation (e.g., rizatriptan wafer) may be considered for patients who desire a discreet and convenient oral dosage form.
Frequent use and rebound headache: It must be remembered that the triptans are symptomatic medications, most of which have short half-lives. Some patients have found that they need to take them on a very frequent basis, having tried appropriate prophylactic medication in the past and failed. The question of whether this causes problems has been reviewed by Limmroth, 48 who found that frequent usage of zolmitriptan and naratriptan may produce rebound headaches. Overuse of sumatriptan has also been reported to result in medication-induced/chronic headache. 49, 50 In the author's (MJG) experience, the use of a triptan for a number of years may lead to refractoriness. The headache may recur faster and the benefit tends to be less complete; this needs to be studied further. Manufacturers do not offer much guidance concerning maximum recommended usage over a longer period of time. Maximum doses per 24-hour period are generally stated but guidelines regarding maximum monthly usage are not provided. Many clinicians would set a limit of between 12 to 18 doses of a triptan per month; however, data supporting or refuting this recommendation are lacking.
CONCLUSION
In summary, the triptans are effective symptomatic medications for acute migraine attacks. They represent a great advance in migraine management and enhance the quality of life of migraineurs. Sumatriptan has the most extensive data supporting its efficacy, tolerability and safety. Newer triptans may have some advantages over sumatriptan. A l t h o u g h differences exist among the triptans, they appear to be relatively small. Each triptan is efficacious and each has its place. Individual patients may find one more effective and/or better tolerated than another. If a patient does not respond to, or tolerate, one triptan, others may be tried. However, it must be remembered that there still exists a sizable minority of patients in whom triptans are not effective or use is limited by adverse events. Selection of a suitable delivery system, based on the characteristics of an individual patient's attacks and/or patient preference, is also important. It is too soon to determine which triptan is best. Further direct comparative trials may assist in identifying patients that may benefit from a particular triptan.
